About the Company
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Beam Therapeutics Inc.
JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy Rating
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the Best Small-Cap Growth Stocks to Buy Right Now. On August 8, JonesTrading ...
Beam Therapeutics: A Slow-Developing Story
Beam Therapeutics' base editing technology shows early promise in sickle cell and AATD, but commercial success is years away ...
Cathie Wood Snaps Up $17 Million Robinhood Stake on the Dip
Aug 20 - Cathie Wood's ARK Invest funds moved actively across fintech and biotech names on August 19, buying into weakness ...
Beam Therapeutics Stock Surges After FDA Grants RMAT Designation
Beam Therapeutics Inc. (NASDAQ:BEAM) shares jumped 12% following the announcement that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation ...
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing ...
MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data ...
Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock ...
Beam Therapeutics Inc. (NASDAQ:BEAM) also exhibited strong execution across its priority hematology and liver genetic disease programs in fiscal Q3 2024, with progress in patient enrollment ...
Beam Therapeutics Inc. (NASDAQ: BEAM )
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against other best gene-editing ...
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Acquired by Bank of New ...
Beam Therapeutics Inc. has a 52 week low of $20.84 and a 52 week high of $36.75. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 ...
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue ... - Nasdaq
Beam Therapeutics Inc.Which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.01 million for the quarter ended June 2021, missing the Zacks Consensus Estimate ...
Will Beam Therapeutics Inc. (BEAM) Report Negative Q1 Earnings? What ...
Wall Street expects a year-over-year increase in earnings on higher revenues when Beam Therapeutics Inc. (BEAM) reports results for the quarter ended March 2021. While this widely-known consensus ...
Similar Companies
Loading the latest forecasts...